Skip directly to content


  • Information on ELIQUIS

    ELIQUIS® is approved in Australia for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors and for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults.

  • Education & media

    Education slides, videos and information resources

  • ELIQUIS Support Materials

    Information and resources to assist you and your patients at every touch point of the patient's journey

Real-world research presented

  • Clinical trial information
    Randomised clinical trials and real-world research come together to help inform treatment decisions. What does this mean? Real-world data complement randomised clinical trial results to provide additional information to assist...



  1. Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-992.